We found that the expression of TPM4 was significantly enhanced compared to normal tissues in breast invasive carcinoma (BRCA), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), esophageal carcinoma (ESCA), glioblastoma (GBM), lower-grade glioma (LGG), head and neck squamous cell carcinoma (HNSC), acute myeloid leukemia (LAML), liver hepatocellular carcinoma (LIHC), ovarian cancer (OV), pancreatic adenocarcinoma (PAAD), stomach adenocarcinoma (STAD) and testicular germ cell tumor (TGCT). This evidence concerns the gene TPM4 and ovarian carcinoma.